Fibromyalgia - US Drug Forecast and Market Analysis to 2023
The fibromyalgia market is relatively new and not yet established. Three drugs currently dominate the sales across the 7MM and form the core treatment options; Lyrica, Cymbalta and Savella are all approved in the US while only the former is approved in Japan. Since these drugs are also available in the 5EU for other indications, they are prescribed as off-label therapies. A handful of other genericized products also provide off-label usage including antidepressants, anti-epileptics, opioids and muscle relaxants. Although Lyrica, Cymbalta and Savella can provide an effective treatment regimen, there are ample opportunities for the development of alternative treatment choices which can expand the medications available to patients, providing improvement in efficacy, safety and compliance. By 2023, there will be four new entrants to the market (Lyrica CR, TNX-102 SL, DS-5565 and TD-9855). These new products will help to drive market growth and offset some of the patent expiries of the leading brands during the forecast period. Despite these advancements in the treatment landscape, fibromyalgia therapeutic sales growth are expected to be minimal.
The US fibromyalgia market is the largest in the 7MM, owing to its large population size and high drug prices. Cymbalta was the top-selling fibromyalgia brand in the US in 2013, accounting for nearly 41% of the US market with $600.4m in sales. Its strong position was supported by the combination of its efficacy and tolerability profile. However, Cymbalta will lose its leading position due to the sharp generic erosion triggered by its US patent expiry in December 2013.
Overview of Fibromyalgia including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
Detailed information on the key drugs in the US including product description, safety and efficacy profiles as well as a SWOT analysis.
Sales forecast for the top drugs in the US from 2013-2023.
Analysis of the impact of key events as well the drivers and restraints affecting the US Fibromyalgia market.
Reasons to buy
Understand and capitalize by identifying products that are most likely to ensure a robust return
Stay ahead of the competition by understanding the changing competitive landscape for Fibromyalgia.
Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
Make more informed business decisions from insightful and in-depth analysis of drug performance
Obtain sales forecast for drugs from 2013-2023 in the US.